Therapeutic
- Manufacturer
- Western Family Foods | Vi-Jon
- Effective date
- 2012-06-11
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:47:08
Label at a glance#
ProductTherapeutic
Active ingredientCOAL TAR
Label structure9 sections
Contacts and useful links#
Websitewww.westernfamily.com
www.westernfamily.com
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingrident
2.5% Coal Tar Topical Solution
(0.5% Coal Tar)
2.5% Coal Tar Topical Solution
(0.5% Coal Tar)
OTC - PURPOSE SECTION
Purpose
Anti-Dandruff
Anti-Dandruff
INDICATIONS & USAGE SECTION
Use controls the symptoms of:
•dandruff •seborrheic dermatitis •psoriasis
•dandruff •seborrheic dermatitis •psoriasis
WARNINGS SECTION
Warnings
For external use only
For external use only
OTC - ASK DOCTOR SECTION
Ask a doctor before use if you have a condition which covers a large part of the body
OTC - WHEN USING SECTION
When using this product
•do not get into eyes. If contact occurs, rinse eyes thoroughly with water.
•use caution in exposing skin to sunlight after applying this product. It may increase your tendency to sunburn for up to 24 hours after application
•do not use for prolonged periods without consulting a doctor
•do not use with other forms of psoriasis therapy such as ultraviolet radiation or prescription drugs unless directed to do so by a doctor.
•do not get into eyes. If contact occurs, rinse eyes thoroughly with water.
•use caution in exposing skin to sunlight after applying this product. It may increase your tendency to sunburn for up to 24 hours after application
•do not use for prolonged periods without consulting a doctor
•do not use with other forms of psoriasis therapy such as ultraviolet radiation or prescription drugs unless directed to do so by a doctor.
OTC - STOP USE SECTION
Stop use and ask a doctor if condition worsens or does not improve
after regular use of this product as directed.
after regular use of this product as directed.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
DOSAGE & ADMINISTRATION SECTION
Directions
•wet hair thoroughly
•massage shampoo into scalp
•lather. Leave on hair and scalp for several minutes
•rinse and repeat
•for best results use at least twice a week or as directed by a doctor
•wet hair thoroughly
•massage shampoo into scalp
•lather. Leave on hair and scalp for several minutes
•rinse and repeat
•for best results use at least twice a week or as directed by a doctor
OTHER SAFETY INFORMATION
Other information
•store away from direct sunlight
•in rare instances, discoloration of gray, blonde, bleached, or tinted hair may occur
•store away from direct sunlight
•in rare instances, discoloration of gray, blonde, bleached, or tinted hair may occur
INACTIVE INGREDIENT SECTION
Inactive ingredients water, sodium laureth sulfate, cocamide DEA, laureth-4,
ccocamidopropyl betaine, fragrance, sodium chloride, citric acid, imidazolidinyl urea,
tetrasodium EDTA, methylparaben, propylparaben, caramel, FD+C red #4
ccocamidopropyl betaine, fragrance, sodium chloride, citric acid, imidazolidinyl urea,
tetrasodium EDTA, methylparaben, propylparaben, caramel, FD+C red #4
ADVERSE REACTIONS SECTION
Proudly Distributed by
Western Family Foods, Inc.
P.O. Box 4057
Portland, OR 97208
www.westernfamily.com
Western Family Foods, Inc.
P.O. Box 4057
Portland, OR 97208
SPL UNCLASSIFIED SECTION
This product is not manufactured or distributed by the Neutrogena
Corporation, distributor of Neutrogena Therapeutic T/Gel Shampoo
Corporation, distributor of Neutrogena Therapeutic T/Gel Shampoo
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
WESTERN FAMILY
Therapeutic Coal Tar
Anti-Dandruff Shampoo
original formula
Long-Lasting
relief of itching
and flaking
controls the symptoms of:
dandruff, psoriasis, and seborrheic dermatitis
WITH 2.5% COAL TAR TOPICAL SOLUTION USP
COMPARE TO NEUTROGENA
THERAPEUTIC T-GEL SHAMPOO
4.4 FL OZ (130 mL)
image of principal display panel
Therapeutic Coal Tar
Anti-Dandruff Shampoo
original formula
Long-Lasting
relief of itching
and flaking
controls the symptoms of:
dandruff, psoriasis, and seborrheic dermatitis
WITH 2.5% COAL TAR TOPICAL SOLUTION USP
COMPARE TO NEUTROGENA
THERAPEUTIC T-GEL SHAMPOO
4.4 FL OZ (130 mL)

FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 55312-205-23 | 2020-05-21 | C162847 | 48780-1 | 9d75b9d0-ef2f-f424-e053-dadaa90a57ce | Drug Facts |
| 55312-205-23 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-ef2f-f424-e053-dadaa90a57ce | Drug Facts |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| COAL TAR | ACTIVE INGREDIENT | R533ESO2EC | 2 | |
| COAL TAR | ACTIVE MOIETY | R533ESO2EC | 2 | |
| CARAMEL | INACTIVE INGREDIENT | T9D99G2B1R | 2 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| COCAMIDOPROPYL BETAINE | INACTIVE INGREDIENT | 5OCF3O11KX | 2 | |
| COCO DIETHANOLAMIDE | INACTIVE INGREDIENT | 92005F972D | 2 | |
| EDETATE SODIUM | INACTIVE INGREDIENT | MP1J8420LU | 2 | |
| FD&C RED NO. 4 | INACTIVE INGREDIENT | X3W0AM1JLX | 2 | |
| IMIDUREA | INACTIVE INGREDIENT | M629807ATL | 2 | |
| LAURETH-4 | INACTIVE INGREDIENT | 6HQ855798J | 2 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| SODIUM LAURETH SULFATE | INACTIVE INGREDIENT | BPV390UAP0 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- Therapeutic
- Coal Tar
- WATER
- SODIUM LAURETH SULFATE
- COCO DIETHANOLAMIDE
- LAURETH-4
- COCAMIDOPROPYL BETAINE
- SODIUM CHLORIDE
- CITRIC ACID MONOHYDRATE
- IMIDUREA
- EDETATE SODIUM
- METHYLPARABEN
- PROPYLPARABEN
- CARAMEL
- FD&C RED NO. 4
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 55312-205 | 55312-205-23 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| COAL TAR | R533ESO2EC | ACTIB |
| WATER | 059QF0KO0R | IACT |
| SODIUM LAURETH SULFATE | BPV390UAP0 | IACT |
| COCO DIETHANOLAMIDE | 92005F972D | IACT |
| LAURETH-4 | 6HQ855798J | IACT |
| COCAMIDOPROPYL BETAINE | 5OCF3O11KX | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| IMIDUREA | M629807ATL | IACT |
| EDETATE SODIUM | MP1J8420LU | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| CARAMEL | T9D99G2B1R | IACT |
| FD&C RED NO. 4 | X3W0AM1JLX | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE / ORAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INFILTRATION | 648 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION, LIPOSOMAL / EPIDURAL | 11 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRACARDIAC | 1.05 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAMUSCULAR | 5 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / RECTAL | 7 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRADERMAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | GEL / TOPICAL | 4 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | EMULSION / TOPICAL | 0.06 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 360 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | EMULSION / TOPICAL | 0.11 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM / TOPICAL | 120 mg | ||
| LAURETH-4 | LAURETH-4 | 6HQ855798J | SOLUTION / TOPICAL | 5.22 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / AURICULAR (OTIC) | 0.9 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IONTOPHORESIS | 0.1 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION, EXTENDED RELEASE / ORAL | 140.8 mg | ||
| EDETATE SODIUM | EDETATE SODIUM | MP1J8420LU | EMULSION / OPHTHALMIC | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE / ORAL | 238 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GRANULE, FOR SUSPENSION / ORAL | 162 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / TOPICAL | 210 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRA-ARTERIAL | 278 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / EPIDURAL | 0.9 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | JELLY / TOPICAL | 180 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRATHECAL | ADJ PH | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | PASTE, DENTIFRICE / DENTAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVESICAL | 351 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ENDOTRACHEAL | 46.76 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2922 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, CHEWABLE / ORAL | 0.14 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 69 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATHECAL | 9 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAMUSCULAR | 45 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVENOUS | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LOTION / TOPICAL | 6 mg | ||
| EDETATE SODIUM | EDETATE SODIUM | MP1J8420LU | INJECTION / INTRAMUSCULAR | 0.01 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ENEMA / RECTAL | 0.7 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / VAGINAL | 10 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d9bbd71c-cfeb-417d-9f39-9d4939e51280 | ebe1871b-ce17-44a0-90cb-a5e258c89b0c | 2020-04-30 | Warnings | ebe1871b-ce17-44a0-90cb-a5e258c89b0c |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.